Show simple item record

dc.contributor.authorSocinski, M
dc.contributor.authorObasaju, C
dc.contributor.authorGandara, D
dc.contributor.authorHirsch, F
dc.contributor.authorBonomi, P
dc.contributor.authorBunn, P
dc.contributor.authorKim, E
dc.contributor.authorLanger, C
dc.contributor.authorNatale, R
dc.contributor.authorNovello, S
dc.contributor.authorPaz-Ares, L
dc.contributor.authorPérol, M
dc.contributor.authorReck, M
dc.contributor.authorRamalingam, S
dc.contributor.authorReynolds, C
dc.contributor.authorSpigel, D
dc.contributor.authorWakelee, H
dc.contributor.authorThatcher, Nick
dc.date.accessioned2017-12-21T10:07:20Z
dc.date.available2017-12-21T10:07:20Z
dc.date.issued2017-11-23
dc.identifier.citationCurrent and emergent therapy options for advanced squamous-cell lung cancer. 2017, J Thorac Oncolen
dc.identifier.issn1556-1380
dc.identifier.pmid29175116
dc.identifier.doi10.1016/j.jtho.2017.11.111
dc.identifier.urihttp://hdl.handle.net/10541/620733
dc.description.abstractSquamous-cell lung cancer (SqCLC) is a distinct histologic subtype of non-small-cell lung cancer (NSCLC) that is challenging to treat due to specific clinicopathologic characteristics, which include older age, advanced disease at diagnosis, co-morbid diseases, and the central location of tumors. These characteristics have a bearing on treatment outcomes in advanced SqCLC, resulting in a median survival approximately 30% shorter than for patients with other NSCLC subtypes. In the context of the specific features of SqCLC, we review challenges of treating SqCLC and the current guideline-recommended treatments for advanced (metastatic) SqCLC in different patient subpopulations. We also evaluate recently approved treatment options, including necitumumab, afatinib, nivolumab, pembrolizumab, and atezolizumab, discuss the survival benefits associated with each agent in the advanced SqCLC population, and propose a treatment algorithm incorporating these agents for this challenging-to-treat disease. Lastly, we review the preliminary clinical evidence for immunotherapy agents in development for advanced NSCLC.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of thoracic oncology : official publication of the International Association for the Study of Lung Canceren
dc.titleCurrent and emergent therapy options for advanced squamous-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentFlorida Hospital Cancer Institute, Orlando, Floridaen
dc.identifier.journalJournal of Thoracic Oncologyen
html.description.abstractSquamous-cell lung cancer (SqCLC) is a distinct histologic subtype of non-small-cell lung cancer (NSCLC) that is challenging to treat due to specific clinicopathologic characteristics, which include older age, advanced disease at diagnosis, co-morbid diseases, and the central location of tumors. These characteristics have a bearing on treatment outcomes in advanced SqCLC, resulting in a median survival approximately 30% shorter than for patients with other NSCLC subtypes. In the context of the specific features of SqCLC, we review challenges of treating SqCLC and the current guideline-recommended treatments for advanced (metastatic) SqCLC in different patient subpopulations. We also evaluate recently approved treatment options, including necitumumab, afatinib, nivolumab, pembrolizumab, and atezolizumab, discuss the survival benefits associated with each agent in the advanced SqCLC population, and propose a treatment algorithm incorporating these agents for this challenging-to-treat disease. Lastly, we review the preliminary clinical evidence for immunotherapy agents in development for advanced NSCLC.


Files in this item

This item appears in the following Collection(s)

Show simple item record